JLE

European Cytokine Network

MENU

Can interleukin-2 reverse anthracyclin chemoresistance in metastatic soft tissue sarcomas? Results of a prospective clinical phase II trial. Volume 12, numéro 2, June 2001

Auteurs
Oncology Unit, Institut Paoli-Calmettes, 232, boulevard Sainte-Marguerite, 13273 Marseille Cedex 09, France.
  • Page(s) : 239-43
  • Année de parution : 2001

INTRODUCTION Advanced metastatic soft tissue sarcoma (STS) remains incurable in the majority of patients. Chemotherapy has demonstrated moderate activity with low response rate. The most active drugs available are anthracyclin, ifosfamide, and dacarbazine. Anthracyclin is currently considered one of the cornerstones of treatment for metastatic STS, either as a single agent or in combination, and with an average response rate of about 20% [...]